Resource Central is a product of the Pediatric Pandemic Network.

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants

Collections

This resource is featured in the following Collection(s):